e-learning
resources
Virtual 2020
Tuesday, 08.09.2020
Airway diseases
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Is there a problem with short-acting beta-2 agonist monotherapy in asthma?
D. Price (Singapore, Singapore)
Source:
Virtual Congress 2020 – Airway diseases
Session:
Airway diseases
Session type:
State of the art session
Number:
4512
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Price (Singapore, Singapore). Is there a problem with short-acting beta-2 agonist monotherapy in asthma?. Virtual Congress 2020 – Airway diseases
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?
Source: Eur Respir Rev 2015; 25: 54-64
Year: 2016
What predicts short-acting beta agonist (SABA) monotherapy use in children?
Source: Eur Respir J 2004; 24: Suppl. 48, 308s
Year: 2004
Paradoxical bronchoconstriction after administration of beta-2 agonist bronchodilators in COPD patients
Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations
Year: 2021
Efficacy and safety of Long-acting Beta-agonists+Long-acting muscarinic antagonists vs Long-acting Beta-agonists+Inhaled corticosteroids in COPD: a meta-analysis
Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD
Year: 2017
Can long-acting β2 agonists substitute inhaled corticosteroids in stable persistent asthma
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008
Should guidelines be revised for add-on therapy in asthma? A 2 year randomized pragmatic equivalence trial of leukotriene antagonists (LTRAs) and long-acting beta agonists (LABAs) with inhaled corticosteroids (ICS) in primary care
Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care
Year: 2008
Increased doses of inhaled corticosteroids versus addition of long-acting beta2 agonists for treatment of asthma
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010
The effect of additional use of short-acting beta2 agonist on exercise tolerance in patients with COPD on regular long-acting bronchodilators treatments
Source: International Congress 2015 – New insights into exercise and muscle performance
Year: 2015
Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids
Source: Annual Congress 2007 - Respiratory issues in primary care
Year: 2007
The impact of tiotropium on mortality when added to inhaled corticosteroids and long-acting beta agonist therapy in COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Comparison of add-on of leukotriene receptor antagonist vs. long-acting beta2-agonist on FeNO in asthmatic children on regular inhaled budesonide
Source: Eur Respir J 2002; 20: Suppl. 38, 431s
Year: 2002
First line maintenance therapy for asthma: an observational study comparing inhaled corticosteroid monotherapy to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007
Step-up of asthma therapy: an observational study comparing increased inhaled corticosteroid dosage to combination inhaled corticosteroid/long acting beta agonist therapy in UK general practice
Source: Annual Congress 2007 - Traditional and novel approaches to assess and achieve asthma control
Year: 2007
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011
Real-life use and impact of inhaled steroids (ICS) and leukotriene receptor antagonists (LTRA) monotherapy in children with asthma
Source: Annual Congress 2010 - Paediatric asthma treatment and monitoring
Year: 2010
The efficacy and safety of long-acting muscarinic antagonist treatment for COPD
Source: International Congress 2019 – Advances in chronic obstructive pulmonary disease and asthma
Year: 2019
The effect of topical ophthalmic timolol in patients treated for COPD with inhaled beta adrenergic agonist albuterol
Source: Eur Respir J 2006; 28: Suppl. 50, 213s
Year: 2006
Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD
Source: International Congress 2014 – Bronchodilators for asthma and COPD
Year: 2014
Comparison of the efficacy and safety of long-acting anticholinergic and a combination of inhaled steroids and long-acting beta-2 agonist in moderate chronic obstructive pulmonary disease
Source: Annual Congress 2013 –COPD drugs: new findings
Year: 2013
Pharmacokinetics of PF-00610355, a novel inhaled long-acting β
2
-adrenoreceptor agonist
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept